CJC-1295/Ipamorelin: Synergistic GHRH and GHRP Combination in Growth Hormone Research
Research Use Only. This article is for scientific and educational reference only. All products are sold for research purposes and are not intended for human or animal consumption.
Overview
The CJC-1295/Ipamorelin combination pairs two complementary growth hormone secretagogues that act through distinct but synergistic receptor pathways. CJC-1295 (with DAC) is a long-acting GHRH analogue that stimulates GH release through the GHRH receptor, while ipamorelin is a selective GHRP that acts through the GHS-R1a (ghrelin receptor). Together, they activate both major pathways of pituitary GH secretion simultaneously.
This combination has become one of the most studied peptide protocols in GH research due to the complementary pharmacology of its components: CJC-1295's extended half-life (6–8 days) provides sustained GHRH receptor stimulation, while ipamorelin's selectivity for GH release (with minimal effects on cortisol, prolactin, or appetite) provides clean GHS-R1a activation. The result is a potent, selective, and sustained increase in GH secretion.
Mechanism of Action
CJC-1295 component: Binds to pituitary GHRH receptors, activating adenylyl cyclase and increasing intracellular cAMP, which drives GH synthesis and secretion. The DAC modification enables albumin binding and extends the half-life to approximately 6–8 days, providing a sustained GHRH signal.
Ipamorelin component: Acts as a full agonist at GHS-R1a receptors on pituitary somatotrophs, stimulating GH release through phospholipase C-mediated calcium signaling. Ipamorelin's high selectivity for GH release — with minimal stimulation of ACTH, cortisol, or prolactin compared to GHRP-6 and GHRP-2 — makes it a preferred research tool when isolated GH axis effects are the study objective.
Synergistic interaction: The combination of GHRH receptor and GHS-R1a activation produces GH responses that are 2–5 fold greater than either peptide alone. This synergy arises from complementary intracellular signaling pathways (cAMP vs. calcium) and the removal of somatostatin inhibitory tone by the GHRP component.
Key Research Findings
Research combining GHRH analogues with GHRPs has consistently demonstrated synergistic GH release. Studies using CJC-1295 combined with ipamorelin have reported peak GH concentrations 3–10 fold above baseline, with the magnitude dependent on dose, timing, and metabolic state. The combination has been studied in models of GH deficiency, aging-associated GH decline, and body composition research.
Research in animal models has demonstrated that the CJC-1295/ipamorelin combination produces improvements in lean mass, reductions in fat mass, and increases in bone mineral density consistent with GH/IGF-1 axis stimulation. Studies examining sleep architecture have reported increases in slow-wave sleep duration, during which endogenous GH secretion is highest, suggesting that the combination may amplify physiological GH release patterns.
Research Considerations
The combination is typically studied with ipamorelin administered more frequently (given its shorter half-life of approximately 2 hours) alongside less frequent CJC-1295 dosing. Research protocols should account for the different pharmacokinetic profiles of the two components when designing dosing schedules and blood sampling timepoints. Both peptides are supplied as lyophilized powders requiring reconstitution with bacteriostatic water.
Research Use Only. This article is for scientific and educational reference. All products are sold for research purposes only and are not intended for human or animal consumption.